The cyclophilin inhibitor Debio-025 shows potent anti–hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus
Robert Flisiak(Medical University of Białystok), Piétro Scalfaro(Debiopharm (Switzerland)), Michael Bobardt(Scripps Research Institute), Ewa Siwak(Medical University of Białystok), Józef Higersberger, Suganya Selvarajah, Philippe Gallay(Scripps Research Institute), Pierre Grosgurin(Debiopharm (Switzerland)), Andrzej Horban(Medical University of Warsaw), Iwona Cielniak, Valerie Nicolas‐Métral(Debiopharm (Switzerland)), Christian Aeschlimann(Novartis (Switzerland)), Hervé Porchet(University of California, San Francisco), R. Crabbé(Debiopharm (Switzerland)), Jean‐Maurice Dumont(Debiopharm (Switzerland)), Alicja Wiercińska‐Drapało(Medical University of Białystok)
Cited by 223
Related Papers
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
|Science|1996|4.9k
Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum
|Clinical Pharmacology & Therapeutics|1988|625
HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway
|Proceedings of the National Academy of Sciences|1997|483
Influence of Hepatitis C Virus Infection on HIV‐1 Disease Progression and Response to Highly Active Antiretroviral Therapy
|The Journal of Infectious Diseases|2005|385